Fundraising Fox
Passage Bio
NASDAQ: PASGPhiladelphia, US · Founded 2017 · Delaware corporation · 38 employees on LinkedIn · 13 known investors
Find your way into Passage Bio
Sign up to see every warm intro you have to Passage Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Passage Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Passage Bio is a biotechnology company developing treatments for central nervous system (CNS) diseases, with a focus on neurodegenerative conditions. It works on therapies for patients living or born with CNS diseases and their families.
Founders & leadership
Board
Investors · 13
How we know: Frazier Life Sciences's portfolio page · the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
How we know: funding news · globenewswire.com · Not right? Tell us
How we know: a partner's Signal profile · funding news · globenewswire.com · Not right? Tell us
How we know: funding news · globenewswire.com · Not right? Tell us
How we know: the S-1 prospectus · funding news · globenewswire.com · Not right? Tell us
How we know: the S-1 prospectus · funding news · globenewswire.com · Not right? Tell us
How we know: the S-1 prospectus · funding news · globenewswire.com · Not right? Tell us
Also in the syndicate · 4
Reported raises · per SEC filings
Form D private placements$110M disclosed across 1 of 3 rounds · 1900–2019
▶$110MraisedSep 2019 · 15 investors · Other Health CareRule 506(b)
- Patrick HeronDirector
- Carl GordonDirector
- Tadataka YamadaExecutive Officer, Director, Promoter
- Saqib IslamDirector
- Thomas Street Address 1 WoiwodeDirector
- Stephen SquintoExecutive Officer, Director
- Offering amount
- $110M
- Amount sold
- $110M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b, 3C, 3C.1
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 5
Companies working in the same space as Passage Bio.
In the news
Frequently asked questions
- What does Passage Bio do?
- Passage Bio is a biotechnology company developing treatments for central nervous system (CNS) diseases, with a focus on neurodegenerative conditions. It works on therapies for patients living or born with CNS diseases and their families.
- Who are Passage Bio's investors?
- Passage Bio's investors include Frazier Life Sciences, Access Biotechnology, Frazier Healthcare Partners, Lilly Asia Ventures, New Leaf Venture Partners, OrbiMed, Sphera Funds Management, Versant Ventures and 1 more.
- How much funding has Passage Bio raised?
- Passage Bio has disclosed $110M raised across 1 of its 3 known rounds.
- Where is Passage Bio headquartered?
- Passage Bio is headquartered in Philadelphia, US.